Loading company…
RIGERNA researches and develops small nucleic acid drugs, including liver-targeted siRNA candidates.
Founded in 2022 and based in Suzhou, China, RIGERNA researches and develops small nucleic acid drugs through its RIHOST®, RICMO® and LICOD® platforms. Its liver-targeted siRNA candidate RG002C0106 for complement C3 received clinical approval in Australia and China in August 2024. In March 2026, the company raised CNY 200 million in pre-Series A funding led by Kangjun Capital, with participation from Delian Capital, Huatai Zijin Investment, Sealand Innovation, Lenovo Capital and Incubator Group, Guolian Group, and GSR United Capital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in